Organic compounds -- part of the class 532-570 series – Organic compounds – Unsubstituted hydrocarbyl chain between the ring and the -c-...
Patent
1995-02-21
1997-03-04
Eisenschenk, Frank C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Unsubstituted hydrocarbyl chain between the ring and the -c-...
5483041, 536 111, 536 174, 536 53, 424 9363, C07D25702, C07D49504, A61K 31415, C07H 1704
Patent
active
056080603
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to methods, compounds, compositions and kits useful for delivering to a target site a targeting moiety that is conjugated to one member of a ligand/anti-ligand pair. After localization and clearance of the targeting moiety conjugate, direct or indirect binding of a diagnostic or therapeutic agent conjugate at the target site occurs. Methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as the related compounds, are also disclosed. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are set forth.
BACKGROUND OF THE INVENTION
Conventional cancer therapy is plagued by two problems. The generally attainable targeting ratio (ratio of administered dose localizing to tumor versus administered dose circulating in blood or ratio of administered dose localizing to tumor versus administered dose migrating to bone marrow) is low. Also, the absolute dose of radiation or therapeutic agent delivered to the tumor is insufficient in many cases to elicit a significant tumor response. Improvement in targeting ratio or absolute dose to tumor is sought.
SUMMARY OF THE INVENTION
The present invention is directed to diagnostic and therapeutic pretargeting methods, moieties useful therein and methods of making those moieties. Such pretargeting methods are characterized by an improved targeting ratio or increased absolute dose to the target cell sites in comparison to conventional cancer therapy.
The present invention describes chelate-biotin compounds and radiohalogenated biotin compounds useful in diagnostic and therapeutic pretargeting methods. The present invention also provides targeting moiety-ligand, such as biotin, compounds useful in diagnostic and therapeutic pretargeting methods. Selection of moieties and methodologies used to enhance internalization (of chemotherapeutic drugs, for example) or to enhance retention at the target cell surface (of radionuclides, for example) is also discussed.
In addition, the present invention provides targeting moiety-anti-ligand, such as avidin or streptavidin, compounds useful in diagnostic and therapeutic pretargeting methods. Other ligand-anti-ligand systems including the zinc finger protein-dsDNA fragment binding pair are also contemplated. Preparation and purification of such anti-ligand-targeting moiety compounds are also discussed.
The present invention also provides clearing agents to facilitate the removal of circulating targeting moiety-ligand (two-step) or targeting moiety-anti-ligand (two-step) or anti-ligand (three-step) from the mammalian recipient. Preferred clearing agents are classifiable as galactose-based and non-galactose-based. Within each category, preferable clearing agents are polymeric or protein based. Particulate agents, extracorporeal procedures and in vivo devices are also contemplated for use in the practice of the present invention.
Also, the present invention is directed to methods using streptavidin as an anti-ligand to enhance retention of radionuclide at target cell sites, with pretargeting protocols constituting one such method. More specifically, these embodiments of the present invention involve either (1) targeting moiety-streptavidin-radionuclide (with the radionuclide bound to streptavidin directly or through a chelate or linker), as well as (2) targeting moiety-biotin administered prior to streptavidin-radionuclide, or (3) biotin-radionuclide bound to a pretargeted streptavidin containing molecule.
The present invention further provides pretargeting methods employing intraarterial or other local administration of the therapeutic moiety-containing molecule to achieve greater localization thereof to artery-supplied target cell populations. Other methods of the present invention involve administration of short duration bone marrow protecting agents or vascular permeability enhancing agents prior to radionuclide-ligand molecule or radionuclide-anti-ligand molecule administration. F
REFERENCES:
patent: 4639365 (1987-01-01), Sherry
patent: 4647447 (1987-03-01), Gries et al.
patent: 4678667 (1987-07-01), Meares et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4923985 (1990-05-01), Gansow et al.
patent: 5141966 (1992-08-01), Porath
patent: 5246692 (1993-09-01), Gansow et al.
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5277895 (1994-01-01), Platzek et al.
patent: 5326778 (1994-07-01), Rosebrough
Rosebrough, J. Pharmacol. Exp. Ther., 1993, 265(1):408 Wu et al., Nucl. Med. Biol., 1992, 19(2):239.
Weber et al., "Enhanced Kidney Clearance with an Ester-Linked .sup.99m Tc-Radiolabeled Antibody Fab'-Chelator Conjugate," Bioconjugate Chem., vol. 1, pp. 431-437, 1990.
Wall et al., "The Galactose-Specific Recognition System of Mammalian Liver: the Route of Ligand Internalization in Rat Hepatocytes," Cell, vol. 21, pp. 79-93, 1980.
Lee et al., "2-Imino-2-methoxyethyl 1-Thioglycosides: New Reagents for Attaching Sugars to Proteins," Biochem., vol. 15, No. 18, pp. 3956-3962, 1976.
Krantz et al., "Attachment of Thioglycosides to Proteins: Enhancement of Liver Membrane Binding," Biochem., vol. 15, No. 18, pp. 3963-3968, 1976.
Van Der Sluijs et al., "Drug Targeting to the Liver with Lactosylated Albumins: Does the Glycoprotein Target the Drug or is the Drug Targeting the Glycoprotein?", Hepatology, vol. 6, No. 4, pp. 723-728, 1986.
Sharon et al., "Carbohydrates in Cell Recognition", Scientific American, vol. 268, No. 1, Jan. 1993, pp. 82-89.
Morell et al., "The Role of Sialic Acid in Determining the Survival of Glycoproteins in the Circulation," J. Biol. Chem., vol. 246, No. 5, pp. 1461-1467, 1971.
Tolleshaug, "Binding and Internalization of Asialo-glycoproteins by Isolated Rat Hepatocytes," Int. J. Biochem., vol. 13, pp. 45-51, 1981.
Galli et al., "A Radiopharmaceutical for the Study of the Liver: .sup.99m Tc-DTPA-Asialo-Orosomucoid I: Radiochemical and Animal Distribution Studies," J. Nucl. Med., vol. 32, No. 2, pp. 110-116, 1988.
Sharma et al., "Inactivation and Clearance of an anti-CEA carboxypeptidase G2 Conjugate in Blood after Localization in a Xenograft Model," Br. J. Cancer, vol. 61, pp. 659-662, 1990.
Jansen et al., "Hepatic Endocytosis of Various Types of Mannose-terminated Albumins," J. of Biological Chem., vol. 266, No. 5, pp. 3343-3348, 1991.
Sheldon et al., "Targeting of [.sup.111 In]Biocytin to Cultured Ovarian Adenocarcinoma Cells Using Covalent Monoclonal Antibody-Streptavidin Conjugates," Appl. Radiat. Isot., vol. 43, No. 11, pp. 1399-1402, 1992.
Goodwin, "New Methods for Localizing Infection: A Role for Avidin-Biotin?," J. Nucl. Med., vol. 33, No. 10, pp. 1816-1818, 1992.
Goodwin et al., "Pretargeted Immunoscintigraphy: Effect of Hapten Valency on Murine Tumor Uptake," J. Nucl. Med., vol. 33, No. 11, pp. 2006-2013, 1992.
McMurry et al., "Convenient Synthesis of Bifunctional Tetraaza Macrocycles," Bioconjugate Chem., vol. 3, No. 2, pp. 108-117, 1992.
Renn and Meares, "Large-Scale Synthesis of the Bifunctional Chelating Agent 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic Acid, and the Determination of Its Enatiomeric Purity by Chiral Chromatography," Bioconjugate Chem., vol. 3, No. 6, pp. 563-569, 1992.
Koch and M acke, ".sup.99m Tc Labeled Biotin Conjugate in a Tumor Pretargeting Approach with Monoclonal antibodies," Angew. Chem. Intl. Ed. Engl., vol. 31, No. 11, pp. 1507-1509, 1992.
Wu et al., "Investigations of N-linked Macrocycles for .sup.111 In and .sup.90 Y Labeling of Proteins," Nucl. Med. Biol. Int. J. Radiat. Appl. Instrum. Part B, vol. 19, No. 2, pp. 239-244, 1992.
Goodwin et al., Abstract No. 232, "Pharmacokinetics of Biotin-Chelate Conjugates for Pretargeted Avidin-Biotin Immunoscintigraphy," J. Nucl. Med. p. 880, 1992.
Dischino et al., "Synthesis of Nonionic Gadolinium Chelates Useful as Contrast Agents for Magnetic Resonance Imaging. 1,4,7-Tris(carboxymethyl)-10-substituted-1,4,7,10-tetraazacyclododecanes and Their Corresponding Gadolinium Chelates," Inorg. Chem., vol. 30, pp
Axworthy Donald B.
Gustavson Linda M.
Reno John M.
Theodore Louis J.
Eisenschenk Frank C.
NeoRx Corporation
LandOfFree
Biotinidase-resistant biotin-DOTA conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biotinidase-resistant biotin-DOTA conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biotinidase-resistant biotin-DOTA conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2147044